Sarepta, in shadow of FDA setback, marks gene therapy progress

Three patients with a type of limb-girdle muscular dystrophy were able to stand up, walk and run faster after treatment with Sarepta Therapeutics' gene therapy SRP-9003, which is on track to begin testing with a higher dose.